-
Mashup Score: 17
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9AbbVie Reports First-Quarter 2024 Financial Results - 12 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5AbbVie Reports First-Quarter 2024 Financial Results - 12 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis - 20 day(s) ago
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine - 26 day(s) ago
– Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine – Seventy percent of…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 17AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - 1 month(s) ago
Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ — AbbVie…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 15U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients - 2 month(s) ago
– The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive,…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 12AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation - 2 month(s) ago
– Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation – OSE Immunotherapeutics to receive an upfront…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5
– A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
This week, our Chief Operations Officer & Chief Scientific Officer joined local Rhineland-Palatinate leaders at the groundbreaking for LUnA, our new R&D building in Ludwigshafen, Germany, where we’ve invested 150 million euros in #innovation & #research. https://t.co/wrAQWscydB https://t.co/l3QkTIQEv8